Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children - Summary - MDSpire
Advertisement
Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children
To investigate the performance of macrolide antibiotics for treating Mycoplasma pneumoniae pneumonia (MPP) in children with or without Mycoplasma pneumoniae resistance genes, highlighting the impact of resistance on treatment outcomes.
Key Findings:
217 MPP patients were included; 188 classified as MRMP (86.6% rate) and 29 as MSMP.
Higher MP DNA load in MRMP patients in both throat swabs and bronchoalveolar lavage fluid (P < 0.05).
Longer duration of macrolide therapy in MRMP patients (7.66 days vs. 6.38 days, P < 0.01).
Incidence of severe MPP was 5.8% in MRMP and 17.2% in MSMP (not statistically significant, P = 0.071).
Interpretation:
Macrolide treatment shows comparable clinical effectiveness in both MRMP and MSMP patients, suggesting that treatment decisions should consider resistance profiles.
Limitations:
Retrospective design may introduce bias, affecting the reliability of results.
Limited generalizability due to single-center study, which may not reflect broader populations.
Further evaluation needed on the association between MP DNA load and treatment duration, as this could influence clinical outcomes.
Conclusion:
The study indicates that macrolide antibiotics remain effective for treating MPP in both MRMP and MSMP pediatric patients, warranting further research on treatment duration and outcomes.
